🇺🇸 SCH 530348 in United States

11 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 28 March 2025 – 28 March 2026
• Total reports: 11

Most-reported reactions

1. Cardiac Failure — 2 reports (18.18%)
2. Anaemia — 1 report (9.09%)
3. Arrhythmia Supraventricular — 1 report (9.09%)
4. Basophil Count Increased — 1 report (9.09%)
5. Cardiac Enzymes Increased — 1 report (9.09%)
6. Cardiogenic Shock — 1 report (9.09%)
7. Chest Pain — 1 report (9.09%)
8. Deep Vein Thrombosis — 1 report (9.09%)
9. Dialysis — 1 report (9.09%)
10. Dyspnoea — 1 report (9.09%)

Source database →

Frequently asked questions

Is SCH 530348 approved in United States?

SCH 530348 does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for SCH 530348 in United States?

Merck Sharp & Dohme LLC is the originator. The local marketing authorisation holder may differ — check the official source linked above.